Abstract
OBJECTIVE: Colorectal cancer is a common and often fatal malignancy, and predicting survival can help guide treatment decisions. This study aimed to investigate the impact of clinicopathological characteristics and nutritional status on survival in patients with metastatic colorectal cancer receiving first-line treatment with 5-fluorouracil in combination with monoclonal antibodies (bevacizumab, cetuximab, or panitumumab). METHODS: This prospective, non-interventional, observational, single-center study included 150 adult patients with metastatic colorectal cancer undergoing first-line therapy. Demographic data, cancer-related characteristics, laboratory parameters, and nutritional status assessed via the Mini Nutritional Assessment-Short Form were recorded prior to treatment initiation. Mini Nutritional Assessment-Short Form scores of 12-14, 8-11, and 0-7 were used to define normal nutritional status, risk of malnutrition, and malnutrition, respectively. RESULTS: The mean ages of patients without and with malnutrition were 60±11 and 62±11 years, respectively. Median progression-free survival and overall survival were 12 and 22 months, respectively. Multivariate analysis identified alcohol history (HR=2.83; 95%CI 1.27-6.34; p=0.011) and Mini Nutritional Assessment-Short Form≤7 (HR=1.93; 95%CI 1.09-3.45; p=0.025) as significant predictors of shorter progression-free survival. Mini Nutritional Assessment-Short Form ≤7 (HR=2.96; 95%CI 1.80-4.89; p<0.001) was also significantly associated with decreased overall survival. CONCLUSION: Among patients with metastatic colorectal cancer receiving first-line therapy, malnutrition (Mini Nutritional Assessment-Short Form≤7) and a history of alcohol use were associated with poorer survival outcomes. These findings underscore the importance of routine nutritional assessment and support the need for further prospective multicenter studies to validate these results.